Cargando…
Mesenchymal stromal cells for acute graft‐versus‐host disease: response at 1 week predicts probability of survival
Mesenchymal stromal cells (MSCs) have been successfully used for the treatment of steroid‐resistant graft‐versus‐host‐disease (GvHD). However, the lack of early predictors of clinical responses impacts on the time at which to add further treatment and consequently the design of informative clinical...
Autores principales: | Galleu, Antonio, Milojkovic, Dragana, Deplano, Simona, Szydlo, Richard, Loaiza, Sandra, Wynn, Robert, Marks, David I., Richardson, Deborah, Orchard, Kim, Kanfer, Edward, Tholouli, Eleni, Saif, Muhammad, Sivaprakasam, Ponni, Lawson, Sarah, Bloor, Adrian, Pagliuca, Antonio, Potter, Victoria, Mehra, Varun, Snowden, John A., Vora, Ajay, Kishore, Bhuvan, Hunter, Hannah, Apperley, Jane F., Dazzi, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916615/ https://www.ncbi.nlm.nih.gov/pubmed/30637732 http://dx.doi.org/10.1111/bjh.15749 |
Ejemplares similares
-
Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation
por: Marks, David I, et al.
Publicado: (2011) -
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
por: Cook, Gordon, et al.
Publicado: (2019) -
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
por: Brümmendorf, Tim H, et al.
Publicado: (2015) -
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
por: Corazzelli, Gaetano, et al.
Publicado: (2011) -
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
por: Hillmen, Peter, et al.
Publicado: (2013)